How I treat diffuse large B-cell lymphoma

ESMO Open

article

T. Melchardt¹  A. Egle¹  R. Greil¹ 

[1] IIIrd Medical Department at the Paracelsus Medical University Salzburg, Cancer Center;Salzburg Cancer Research Institute;Austrian Group for Medical Tumor Therapy;Cancer Cluster

关键词: diffuse large B-cell lymphoma;    interim PET;    polatuzumab vedotin;    CAR-T cells;   

DOI  :  10.1016/j.esmoop.2022.100750

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Diffuse large B-cell lymphoma (DLBCL) is usually treated with chemoimmunotherapy in curative intention at initial diagnosis. Novel agents have improved the prognosis of high-risk patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis. Here, we summarize our approach to DLBCL patients in the first-line setting according to their risk profile and other common challenges in clinical practice. We recommend an abbreviated course of chemoimmunotherapy in low-risk patients and a negative interim positron emission tomography. For patients with higher-risk disease, a new combination treatment with polatuzumab vedotin has been approved and is a new option in these patients. We also discuss our approach to patients with high risk for subsequent central nervous system involvement, with leg-type lymphoma or with severe comorbidities.

【 授权许可】

CC BY|CC BY-NC-ND